<DOC>
	<DOCNO>NCT00681187</DOCNO>
	<brief_summary>The primary aim study ass method lanreotide Autogel administration patient neuroendocrine tumour prefer - self/partner administration healthcare provide administration . The study also assess self/partner administration perform without loss efficacy preserve safety profile . The impact self/partner administration resource utilisation cost study . In addition , also assess healthcare provider 's experience two administration practice .</brief_summary>
	<brief_title>Somatuline Autogel Preference Health Economy Study</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<criteria>Provision write informed consent patient partner ( partner administer lanreotide Autogel injection self administration period ) Male female age 18 year age older Treated lanreotide Autogel 90 120 mg every 28th day carcinoid symptom stable dose least 3 month prior inclusion . The patient presume clinically stable come month Neuroendocrine tumour confirm biopsy visible radiology Has history hypersensitivity Investigational Medicinal Product drug similar chemical structure Has abnormal baseline finding , medical condition ( ) laboratory finding , opinion Investigator , might jeopardise patient 's safety decrease chance obtain satisfactory data need achieve objective ( ) study Has life expectancy less year , judge Investigator The patient partner consider competent injection technique , judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>